Results

Total Results: over 10,000 records

Showing results for "stage".

381. Colorectal-Cancer-Protocol_130520 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/colorectal-cancer-staging_research-protocol.pdf
     May 20, 2013 - However, stage is the key determinant of the management strategy. … that is compared against the stage established by the reference standard. … Stage reclassification or clinical decision impact. … Stage reclassification. … The change in stage of the cancer after imaging, compared with the stage determined based on information

382. Colorectal-Cancer-Protocol_130520 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/colorectal-cancer-staging_research-protocol.pdf
     May 20, 2013 - However, stage is the key determinant of the management strategy. … that is compared against the stage established by the reference standard. … Stage reclassification or clinical decision impact. … Stage reclassification. … The change in stage of the cancer after imaging, compared with the stage determined based on information

383. NHQDR Web Site - National Prevention Benchmark Details
     nhqrnet.ahrq.gov/inhqrdr/National/benchmark/table/Type_of_Care/Prevention
     February 19, 2021 - ever received pneumococcal vaccination 69.0 78.7 12.3% Breast cancer diagnosed at advanced stage … (regional, distant stage, or local stage with tumor greater than 2 cm) per 100,000 women age 40 and … over 84.5 74.2 13.8% Colorectal cancer diagnosed at advanced stage (tumors diagnosed at regional … or distant stage) per 100,000 population age 50 and over 63.8 48.9 30.4% Cervical cancer … diagnosed at advanced stage (all invasive tumors) per 100,000 women age 20 and over 10.5 7.7 36.0%

384. Evidence Summary: Lung Cancer: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary4/lung-cancer-screening
     July 30, 2013 - Because early-stage lung cancer is associated with lower mortality than late-stage disease, early detection … Stage II: 0.3% ( n = 4) vs. 0.2% (n = 2) Stage IIIA: 0.6% ( n = 7) vs. 0.3% ( n = 4) Stage … : 31/35     Stage IA: 20/16     Stage IB: 2/1     Stage IIA: 4/4     Stage IIB: 0 … /2     Stage IIIA: 2/4     Stage IIIB: 0/2     Stage IV: 1/0     Unknown: 0/2      … I: 58%   Stage II: 17%   Stage III: 30%   Stage IV: 7%   Additional procedures

385. Archived: Evidence Summary: Lung Cancer: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary4/lung-cancer-screening-december-2013
     July 30, 2013 - Because early-stage lung cancer is associated with lower mortality than late-stage disease, early detection … NR Stage IV: 17% vs. 15% vs. … : 31/35     Stage IA: 20/16     Stage IB: 2/1     Stage IIA: 4/4     Stage IIB: 0 … /2     Stage IIIA: 2/4     Stage IIIB: 0/2     Stage IV: 1/0     Unknown: 0/2      … I: 58%   Stage II: 17%   Stage III: 30%   Stage IV: 7%   Additional procedures

386. Imaging for the Pretreatment Staging of Small Cell Lung Cancer | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/lung-cancer-staging/research
     December 01, 2019 - Skip to main content An official website of the Department of Health & Human Services Careers Contact Us Español FAQs Effective Health Care Program Powered by the Evidence-based Practice Centers …

387. PowerPoint Presentation
     cds.ahrq.gov/sites/default/files/cds/artifact/106/AMIA_presentation.pptx
     January 01, 2012 - onto building decision support and putting it into practice 5 5 How We Designed Healthy Weight Stage … 1: Freehand mockup Stage 2 Wireframe mockup Stage 3 Interactive module Stage 4 User testing, feedback … Stage 5 Redesign, Enhance, Evaluate 6 Stage 1 Quick, easy, low overhead, adaptable Stage 2 Layout … , spacing, internal workflow (white box testing) Stage 3 Interactivity, data handling, processing speed

388. Management of Renal Masses and Localized Renal Cell Carcinoma: Current State of the Evidence | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/renal-cancer/clinician
     July 18, 2017 - for localized renal cell carcinoma range from greater than 85 percent to 95 percent, depending on the stage … Thermal ablation and active surveillance are considered options for patients with clinical stage T1a … Radical nephrectomy is recommended as the standard of care for most patients with clinical stage T2 tumors … CKD stage ≥3: RR 0.88 (0.60 to 1.30) CKD stage ≥3b: RR 2.78 (0.47 to 16.54) CKD stage ≥4: RR 0.76 … CKD stage ≥3: RR 0.39 (0.30 to 0.51) CKD stage ≥3b: RR 0.37 (0.26 to 0.53) CKD stage ≥4: RR 0.76

389. Management of Renal Masses and Localized Renal Cell Carcinoma: Current State of the Evidence (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/renal-cancer_clinician.pdf
     July 01, 2017 - localized renal cell carcinoma range from greater than 85 percent to 95 percent, depending on the stage … Thermal ablation and active surveillance are considered options for patients with clinical stage T1a … Radical nephrectomy is recommended as the standard of care for most patients with clinical stage T2 … CKD stage ≥3: RR 0.88 (0.60 to 1.30) CKD stage ≥3b: RR 2.78 (0.47 to 16.54) CKD stage ≥4: RR 0.76 ( … CKD stage ≥3: RR 0.39 (0.30 to 0.51) CKD stage ≥3b: RR 0.37 (0.26 to 0.53) CKD stage ≥4: RR 0.76 (0.54

390. Management of Renal Masses and Localized Renal Cell Carcinoma: Current State of the Evidence (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/renal-cancer_clinician.pdf
     July 01, 2017 - localized renal cell carcinoma range from greater than 85 percent to 95 percent, depending on the stage … Thermal ablation and active surveillance are considered options for patients with clinical stage T1a … Radical nephrectomy is recommended as the standard of care for most patients with clinical stage T2 … CKD stage ≥3: RR 0.88 (0.60 to 1.30) CKD stage ≥3b: RR 2.78 (0.47 to 16.54) CKD stage ≥4: RR 0.76 ( … CKD stage ≥3: RR 0.39 (0.30 to 0.51) CKD stage ≥3b: RR 0.37 (0.26 to 0.53) CKD stage ≥4: RR 0.76 (0.54

391. Healthcare Cost and Utilization Project (HCUP) KID Notes
     hcup-us.ahrq.gov/db/vars/ds_stage1/kidnote.jsp
     September 01, 2008 - TOOLS KID Description of Data Elements   DS_Stage1 - Disease Staging: Stage … This severity measure includes the disease category and stage for the principal diagnosis and predictive … Uniform Values Variable Description Value Value Description DS_Stage1 Disease Staging: Stage … of Principal Disease Category n.nn Principal Stage .

392. Healthcare Cost and Utilization Project (HCUP) NIS Notes
     hcup-us.ahrq.gov/db/vars/ds_stage1/nisnote.jsp
     September 01, 2008 - TOOLS NIS Description of Data Elements   DS_Stage1 - Disease Staging: Stage … This severity measure includes the disease category and stage for the principal diagnosis and predictive … Uniform Values Variable Description Value Value Description DS_Stage1 Disease Staging: Stage … of Principal Disease Category n.nn Principal Stage .

393. Erythropoiesis-Stimulating-Agents-Utilization Research (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/erythropoiesis-stimulating-agents-utilization_research.pdf
     February 01, 2011 - to 8 percent among beneficiaries in Stage I; from 13 percent to 7 percent in Stage II; from 23 percent … Stage II: The inclusion criteria for the stage II population included beneficiaries: (1) enrolled in … Stage IV: The inclusion criteria for the stage IV population included beneficia- ries: (1) enrolled in … Stage V: The inclusion criteria for the stage V population included beneficiaries: (1) enrolled in Part … Stage VI: The inclusion criteria for the stage VI population included beneficia- ries: (1) enrolled in

394. Erythropoiesis-Stimulating-Agents-Utilization Research (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/erythropoiesis-stimulating-agents-utilization_research.pdf
     February 01, 2011 - to 8 percent among beneficiaries in Stage I; from 13 percent to 7 percent in Stage II; from 23 percent … Stage II: The inclusion criteria for the stage II population included beneficiaries: (1) enrolled in … Stage IV: The inclusion criteria for the stage IV population included beneficia- ries: (1) enrolled in … Stage V: The inclusion criteria for the stage V population included beneficiaries: (1) enrolled in Part … Stage VI: The inclusion criteria for the stage VI population included beneficia- ries: (1) enrolled in

395. Archived: Addendum to Screening for Ovarian Cancer: Evidence Update for the U.S. Preventive Services Task Force Reaffirmation Recommendation Statement: Ovarian Cancer: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/addendum-to-screening-for-ovarian-cancer-evidence-update-for-the-us-preventive-services-task-force-reaffirmation-recommendation-statement/ovarian-cancer-screening-2012
     April 15, 2012 - of ovarian tumors are diagnosed at this stage. … Additionally, the majority (72 percent) of screen-detected cancer cases were late-stage (Stage III or … Overall, 48.3 percent of the invasive cancer cases were early stage (Stage I or II), with no significant … stage distribution difference between the two groups. … might be more likely to identify early-stage, slow-growing tumors than later screening cycles.

396. Addendum to Screening for Ovarian Cancer: Evidence Update for the USPSTF Reaffirmation Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/QtuWfedsMmUb_sAuKWdsGg
     December 31, 2014 - , only 15 percent of ovarian tumors are diagnosed at this stage. … Additionally, the majority (72 percent) of screen-detected cancer cases were late-stage (Stage III … Overall, 48.3 percent of the invasive cancer cases were early stage (Stage I or II), with no significant … stage distribution difference between the two groups. … might be more likely to identify early-stage, slow-growing tumors than later screening cycles.

397. Topic 0410 Imaging to Diagnose and Statge SCLC and NSCLC NSD SJ clean (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND-0491-140827.pdf
     February 19, 2014 - that there is insufficient clarity regarding the most effective imaging modalities to diagnose and stage … A review of the evidence on imaging modalities to diagnose and stage lung cancer could aid in the development

398. Topic 0410 Imaging to Diagnose and Statge SCLC and NSCLC NSD SJ clean (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/TND-0491-140827.pdf
     February 19, 2014 - that there is insufficient clarity regarding the most effective imaging modalities to diagnose and stage … A review of the evidence on imaging modalities to diagnose and stage lung cancer could aid in the development

399. Job Aid: Model for Improvement and PDSA Cycles (pdf file)
     www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/ncepcr/resources/job-aid-model-pdsa.pdf
     May 17, 2021 - Four stages of a PDSA cycle Stage 1. … Stage 2. … Stage 3. Study – The practice analyzes the data collected during the Do stage. Stage 4.

400. Job Aid: Model for Improvement and PDSA Cycles (pdf file)
     www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/ncepcr/resources/job-aid-model-pdsa.pdf
     May 17, 2021 - Four stages of a PDSA cycle Stage 1. … Stage 2. … Stage 3. Study – The practice analyzes the data collected during the Do stage. Stage 4.